rsid,chrom,start,ref,alts,genotype,weight,state,conclusion,priority,gene,phenotype,category
rs4244285,10,94781859,G,A,A/A,-1.5,risk,"CYP2C19*2 homozygous — Poor metabolizer. Dramatically reduced clopidogrel activation; increased cardiovascular event risk. Consider prasugrel or ticagrelor. Also affects PPI and SSRI metabolism.",high,CYP2C19,Drug metabolism — poor metabolizer,cyp2c19
rs4244285,10,94781859,G,A,A/G,-0.8,risk,"CYP2C19*2 heterozygous — Intermediate metabolizer. Reduced clopidogrel efficacy; consider alternative antiplatelet therapy. Moderate reduction in PPI and SSRI metabolism.",high,CYP2C19,Drug metabolism — intermediate metabolizer,cyp2c19
rs4244285,10,94781859,G,A,G/G,0.0,neutral,"CYP2C19 normal function at this locus. Standard clopidogrel response expected.",medium,CYP2C19,Drug metabolism — normal,cyp2c19
rs4986893,10,94780653,G,A,A/A,-1.5,risk,"CYP2C19*3 homozygous — Poor metabolizer. Complete loss of CYP2C19 function. Same clinical implications as *2 homozygous.",high,CYP2C19,Drug metabolism — poor metabolizer,cyp2c19
rs4986893,10,94780653,G,A,A/G,-0.8,risk,"CYP2C19*3 heterozygous — Intermediate metabolizer. One non-functional allele. Reduced drug activation.",high,CYP2C19,Drug metabolism — intermediate metabolizer,cyp2c19
rs4986893,10,94780653,G,A,G/G,0.0,neutral,"CYP2C19 normal function at *3 locus.",medium,CYP2C19,Drug metabolism — normal,cyp2c19
rs12248560,10,94761900,C,T,T/T,1.0,significant,"CYP2C19*17 homozygous — Ultra-rapid metabolizer. ~2x increased transcription. May cause subtherapeutic levels of PPIs and SSRIs. Enhanced clopidogrel activation (potentially increased bleeding risk).",high,CYP2C19,Drug metabolism — ultra-rapid metabolizer,cyp2c19
rs12248560,10,94761900,C,T,C/T,0.5,significant,"CYP2C19*17 heterozygous — Rapid metabolizer. Moderately increased enzyme activity. Clinical significance depends on co-occurring *2/*3 alleles (diplotype).",medium,CYP2C19,Drug metabolism — rapid metabolizer,cyp2c19
rs12248560,10,94761900,C,T,C/C,0.0,neutral,"CYP2C19 normal transcription rate at *17 locus.",medium,CYP2C19,Drug metabolism — normal,cyp2c19
rs3892097,22,42128945,C,T,T/T,-1.5,risk,"CYP2D6*4 homozygous — Poor metabolizer. No functional CYP2D6 enzyme. Codeine ineffective (no morphine conversion). Tamoxifen ineffective (no endoxifen). Increased adverse effects from tricyclic antidepressants.",high,CYP2D6,Drug metabolism — poor metabolizer,cyp2d6
rs3892097,22,42128945,C,T,C/T,-0.7,risk,"CYP2D6*4 heterozygous — Intermediate metabolizer. Reduced but not absent enzyme activity. May need dose adjustments for CYP2D6 substrates.",high,CYP2D6,Drug metabolism — intermediate metabolizer,cyp2d6
rs3892097,22,42128945,C,T,C/C,0.0,neutral,"CYP2D6 normal function at *4 locus. Standard metabolism of codeine, tamoxifen, and psychiatric medications.",medium,CYP2D6,Drug metabolism — normal,cyp2d6
rs1799853,10,94942290,C,T,T/T,-0.8,risk,"CYP2C9*2 homozygous — Reduced function. Approximately 20% lower warfarin dose required. Increased bleeding risk at standard doses. Also affects NSAID and phenytoin metabolism.",high,CYP2C9,Warfarin sensitivity — reduced metabolism,cyp2c9
rs1799853,10,94942290,C,T,C/T,-0.4,risk,"CYP2C9*2 heterozygous — Mildly reduced function. ~10% warfarin dose reduction may be needed. Monitor INR closely during initiation.",medium,CYP2C9,Warfarin sensitivity — mildly reduced,cyp2c9
rs1799853,10,94942290,C,T,C/C,0.0,neutral,"CYP2C9 normal function at *2 locus. Standard warfarin metabolism.",medium,CYP2C9,Warfarin metabolism — normal,cyp2c9
rs1057910,10,94981296,A,C,C/C,-1.3,risk,"CYP2C9*3 homozygous — Severely reduced function. ~50% lower warfarin dose required. Highest bleeding risk genotype. Mandatory dose adjustment for warfarin and phenytoin.",high,CYP2C9,Warfarin sensitivity — severely reduced metabolism,cyp2c9
rs1057910,10,94981296,A,C,A/C,-0.6,risk,"CYP2C9*3 heterozygous — Moderately reduced function. ~25% lower warfarin dose. Clinically significant; include in pharmacogenomic dosing algorithms.",high,CYP2C9,Warfarin sensitivity — moderately reduced,cyp2c9
rs1057910,10,94981296,A,C,A/A,0.0,neutral,"CYP2C9 normal function at *3 locus. Standard warfarin metabolism.",medium,CYP2C9,Warfarin metabolism — normal,cyp2c9
rs35599367,7,99768693,C,T,T/T,-1.0,risk,"CYP3A4*22 homozygous — Reduced expression. Significantly lower CYP3A4 activity. Lower statin doses needed; higher tacrolimus/cyclosporine trough levels. Monitor closely.",high,CYP3A4,Statin/immunosuppressant metabolism — reduced,cyp3a4
rs35599367,7,99768693,C,T,C/T,-0.5,risk,"CYP3A4*22 heterozygous — Moderately reduced expression. May benefit from lower statin starting dose. Monitor immunosuppressant levels.",medium,CYP3A4,Statin/immunosuppressant metabolism — moderately reduced,cyp3a4
rs35599367,7,99768693,C,T,C/C,0.0,neutral,"CYP3A4 normal expression. Standard metabolism of statins and immunosuppressants.",medium,CYP3A4,Drug metabolism — normal,cyp3a4
